PERIPHERAL T CELL LYMPHOMA
Clinical trials for PERIPHERAL T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy offers hope for rare blood cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (tazemetostat, linperlisib, and golidocitinib) in people with a type of lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination can shrink tumors and control the disease. About 48 adults w…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for tough lymphoma: experimental drug BR101801 enters key trial
Disease control Not yet recruitingThis study tests a new drug called BR101801 in 44 people with a rare blood cancer (peripheral T-cell lymphoma) that has returned or not responded to standard therapy. The main goal is to see if the drug can shrink tumors. This is an early-phase trial, so the focus is on safety an…
Matched conditions: PERIPHERAL T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 12, 2026 13:42 UTC